Nkarta (NKTX) Return on Sales (2019 - 2020)
Nkarta (NKTX) posted quarterly Return on Sales of 1371.43% for Q4 2020, up 707.08% quarter-over-quarter from 225.91% in Q3 2020.
Nkarta (NKTX) Return on Sales (2019 - 2020) Analysis & Trends
Nkarta's Return on Sales history runs 2 years deep, the most recent figure standing at 1371.43% for Q4 2020.
- In Q4 2020, Return on Sales changed N/A year-over-year to 1371.43%; the TTM figure through Dec 2020 stood at 1371.43% (changed N/A YoY), while the FY2019 annual figure was 2.05%, changed N/A from the prior year.
- Return on Sales for Q4 2020 stood at 1371.43%, up from 225.91% in the prior quarter.
- The five-year high for Return on Sales was 1371.43% in Q4 2020, with the low at 225.91% in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 0.00% |
| 10 | Nkarta | 199.94 Mn | 199.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 1,371.43% |
| Sep 30, 2020 | -225.91% |
| Sep 30, 2019 | 163.86% |
| Jun 30, 2019 | -21.01% |